These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 31241250)
1. Associations between environmental factors and serological Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma in South China. Zhou T; Yang DW; He YQ; Xue WQ; Liao Y; Zheng MQ; Jia YJ; Yuan LL; Zhang WL; Zeng YX; Jia WH Cancer Med; 2019 Aug; 8(10):4852-4866. PubMed ID: 31241250 [TBL] [Abstract][Full Text] [Related]
2. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis. Hsu WL; Chien YC; Huang YT; Yu KJ; Ko JY; Lin CY; Tsou YA; Leu YS; Liao LJ; Chang YL; Su JY; Liu Z; Wang CP; Terng SD; Hua CH; Lee JC; Yang TL; Kate Hsiao CH; Wu MS; Tsai MH; Liu MJ; Lou PJ; Hildesheim A; Chen CJ; Cancer Med; 2020 Mar; 9(5):1867-1876. PubMed ID: 31925935 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study. Guo J; Cui Z; Zheng Y; Li X; Chen Y Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897 [TBL] [Abstract][Full Text] [Related]
4. The Relationship Between Environmental Factors and the Profile of Epstein-Barr Virus Antibodies in the Lytic and Latent Infection Periods in Healthy Populations from Endemic and Non-Endemic Nasopharyngeal Carcinoma Areas in China. He YQ; Xue WQ; Xu FH; Xu YF; Zhang JB; Yu HL; Feng QS; Chen LZ; Cao SM; Liu Q; Mu J; Zeng YX; Jia WH EBioMedicine; 2018 Apr; 30():184-191. PubMed ID: 29606628 [TBL] [Abstract][Full Text] [Related]
5. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients. Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA. Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915 [TBL] [Abstract][Full Text] [Related]
7. Lack of association between cigarette smoking and Epstein Barr virus reactivation in the nasopharynx in people with elevated EBV IgA antibody titres. Chen Y; Xu Y; Zhao W; Xiao X; Zhou X; Lin L; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z BMC Cancer; 2018 Feb; 18(1):190. PubMed ID: 29444646 [TBL] [Abstract][Full Text] [Related]
8. [Six anti-Epstein-Barr virus antibodies in healthy adults in a high risk area of nasopharyngeal carcinoma]. Yi B; Gu YL; Zong YS; Cheng WM; Ji MF Ai Zheng; 2009 Aug; 28(8):822-6. PubMed ID: 19664327 [TBL] [Abstract][Full Text] [Related]
9. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma. Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891 [TBL] [Abstract][Full Text] [Related]
10. Intermittent abortive reactivation of Epstein-Barr virus during the progression of nasopharyngeal cancer as indicated by elevated antibody levels. Guo X; Li T; Li F; Xu Y; Wang H; Cheng W; Tang J; Zhou G; Chen H; Ng M; Ji M; Ge S; Xia N Oral Oncol; 2019 Jun; 93():85-90. PubMed ID: 31109701 [TBL] [Abstract][Full Text] [Related]
11. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma]. Luo YL; Chen H; Peng SG; Lin JH; Huang PY Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892 [TBL] [Abstract][Full Text] [Related]
12. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA]. Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122 [TBL] [Abstract][Full Text] [Related]
13. Association between HLA alleles and Epstein-Barr virus Zta-IgA serological status in healthy males from southern China. Yuan LL; Deng CM; Xue WQ; He YQ; Wang TM; Zhang JB; Yang DW; Zhou T; Wu ZY; Liao Y; Zheng MQ; Li DH; Cao LJ; Jia YJ; Zhang WL; Xiao RW; Luo LT; Tong XT; Wu YX; Huang JW; Jia WH J Gene Med; 2021 Nov; 23(11):e3375. PubMed ID: 34164868 [TBL] [Abstract][Full Text] [Related]
14. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877 [TBL] [Abstract][Full Text] [Related]
15. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545 [TBL] [Abstract][Full Text] [Related]
16. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma. Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566 [TBL] [Abstract][Full Text] [Related]
17. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282 [TBL] [Abstract][Full Text] [Related]
18. A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma. Liu W; Li H; Sheng H; Liu X; Chi P; Wang X; Mao M Adv Ther; 2020 Oct; 37(10):4280-4290. PubMed ID: 32780356 [TBL] [Abstract][Full Text] [Related]
19. [Diagnostics of nasopharyngeal carcinoma with Epstein-Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4) serological and molecular markers in cases of undetected primary tumor location.]. Senyuta NB; Smirnova KV; Kondratova VN; Ignatova AV; Mudunov AM; Dushenkina TE; Liechtenstein AV; Gurtsevich VE Vopr Virusol; 2019; 64(5):229-237. PubMed ID: 32167688 [TBL] [Abstract][Full Text] [Related]
20. Combined determination of Epstein-Barr virus-related antibodies and antigens for diagnosis of nasopharyngeal carcinoma. Luo YL; Ou GP; Chi PD; Liang YN; Liu YH; Huang MY Ai Zheng; 2009 Jan; 28(1):76-8. PubMed ID: 19448423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]